GB201220899D0 - CD44v6-derived pegylated peptides - Google Patents

CD44v6-derived pegylated peptides

Info

Publication number
GB201220899D0
GB201220899D0 GBGB1220899.7A GB201220899A GB201220899D0 GB 201220899 D0 GB201220899 D0 GB 201220899D0 GB 201220899 A GB201220899 A GB 201220899A GB 201220899 D0 GB201220899 D0 GB 201220899D0
Authority
GB
United Kingdom
Prior art keywords
cd44v6
derived
pegylated peptides
pegylated
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1220899.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karlsruher Institut fuer Technologie KIT
Original Assignee
Karlsruher Institut fuer Technologie KIT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karlsruher Institut fuer Technologie KIT filed Critical Karlsruher Institut fuer Technologie KIT
Priority to GBGB1220899.7A priority Critical patent/GB201220899D0/en
Publication of GB201220899D0 publication Critical patent/GB201220899D0/en
Priority to PCT/EP2013/074353 priority patent/WO2014079914A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1220899.7A 2012-11-21 2012-11-21 CD44v6-derived pegylated peptides Ceased GB201220899D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1220899.7A GB201220899D0 (en) 2012-11-21 2012-11-21 CD44v6-derived pegylated peptides
PCT/EP2013/074353 WO2014079914A1 (en) 2012-11-21 2013-11-21 Cd44v6-derived pegylated peptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1220899.7A GB201220899D0 (en) 2012-11-21 2012-11-21 CD44v6-derived pegylated peptides

Publications (1)

Publication Number Publication Date
GB201220899D0 true GB201220899D0 (en) 2013-01-02

Family

ID=47521469

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1220899.7A Ceased GB201220899D0 (en) 2012-11-21 2012-11-21 CD44v6-derived pegylated peptides

Country Status (2)

Country Link
GB (1) GB201220899D0 (en)
WO (1) WO2014079914A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015021993A1 (en) * 2013-08-13 2015-02-19 Ibcc Holding As Pharmacologically active modified sb101 molecules and uses thereof
GB201421647D0 (en) * 2014-12-05 2015-01-21 Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases
CN113444139B (en) * 2020-03-25 2023-04-21 中国科学院大学 Enhancement of synthesis and enzymatic hydrolysis of pegylated D-amino acid-containing polypeptides

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
EP1391213A1 (en) * 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
ES2343797T3 (en) * 2004-10-14 2010-08-10 Karlsruher Institut Fur Technologie PEPTIDIC COMPOUNDS AND THEIR DERIVATIVES FOR THE TREATMENT OF HUMAN DISEASES THROUGH THE INHIBITION OF THE SIGNALING ROUTE BY GROWTH FACTORS.
US7842467B1 (en) * 2005-05-12 2010-11-30 Celera Corporation Breast disease targets and uses thereof
EP1770099A1 (en) * 2005-09-28 2007-04-04 University of Geneva Method of producing a modified (poly)peptide
US20080199426A1 (en) * 2007-01-11 2008-08-21 Sukhatme Vikas P Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
ATE523204T1 (en) * 2009-02-16 2011-09-15 Karlsruher Inst Technologie CD44V6 PEPTIDES AS BACTERIAL INFECTION INHIBITORS
EP2266593A1 (en) * 2009-06-24 2010-12-29 Karlsruher Institut für Technologie Use of CD44v6 in the treatment of ophthalmic diseases
JP2013502421A (en) * 2009-08-21 2013-01-24 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー Method of using CD44 fusion protein for cancer treatment
MX2013010910A (en) * 2011-03-24 2014-03-27 Neurim Pharma 1991 Neuroprotective peptides.

Also Published As

Publication number Publication date
WO2014079914A1 (en) 2014-05-30

Similar Documents

Publication Publication Date Title
IL291571A (en) Cx3cr1-binding polypeptides
EP2857033A4 (en) Skin-permeating peptide
EP2922877A4 (en) Improved peptide pharmaceuticals
GB201220474D0 (en) Polypeptides
EP2812347A4 (en) Autophagy-inducing peptide
GB201218813D0 (en) Antimicrobial peptides
GB201418188D0 (en) Peptide arrays
GB201115910D0 (en) Peptides
HUE055593T2 (en) Improved cd31 peptides
HK1209138A1 (en) Peptides
HK1203836A1 (en) Bifunctional peptide
GB201200555D0 (en) Peptide
GB201220899D0 (en) CD44v6-derived pegylated peptides
GB201204868D0 (en) Peptides
GB201223114D0 (en) Novel peptide
HK1201752A1 (en) Alternaria peptides
HUE036243T2 (en) Psf1-derived peptides
EP2714717A4 (en) Phoenixin peptides
GB201213672D0 (en) Protein
HK1211952A1 (en) Recombinant protein
GB201220328D0 (en) Peptides
GB201211740D0 (en) Peptides
GB201207895D0 (en) Peptides
GB201200509D0 (en) Peptides
GB201221414D0 (en) Trans-locating peptide

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)